Ethiqa XR® from Fidelis Animal Health, Inc. is the first and only pharmaceutical grade extended-release buprenorphine that’s FDA-affirmed to control post-procedural pain for laboratory mice and rats up to 72 hours after just one injection. See efficacy and safety.
Ethiqa XR is now available through MWI Animal Health, Covetrus, Hanna Pharmaceutical Supply, and Midwest Veterinary Supply
An Ethical Imperative Effective pain management for laboratory animals is an essential need in today’s research. Learn more about industry association guidelines.
Manufactured in Harleysville, Pa.
Important Safety Information For Rats and Mice: Only administer Ethiqa XR by subcutaneous injection. Ethiqa XR is not intended for intravenous, intra-arterial, intrathecal, intramuscular, or intra-peritoneal injection. Do not use on mice or rats with pre-existing respiratory deficiencies. Do not keep rats on wood chip-type bedding after administration of Ethiqa XR. Use caution with concomitant administration of Ethiqa XR with drugs that cause respiratory depression. For Humans: Ethiqa XR should only be administered by a veterinarian or laboratory staff trained in the handling of potent opioids. Protective clothing is recommended to avoid direct contact with human skin or mucus membranes which could result in absorption of buprenorphine and adverse reactions. Not for use in humans. For more information, consult the prescribing information including the boxed warning.